Drug intelligence / Profile preview

adebrelimab + XELOX

Development stage: Unknown
Lead developer: Hengrui Pharmaceutical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous, Oral

Overview

A combination therapy consisting of adebrelimab and XELOX (capecitabine plus oxaliplatin). XELOX is a chemotherapy regimen where oxaliplatin is administered intravenously while capecitabine is taken orally. Oxaliplatin is typically given on day 1 of each cycle, and capecitabine is taken twice daily for 14 days followed by 7 days off in a 21-day cycle. This combination likely leverages the anti-cancer effects of XELOX chemotherapy with the potential immunotherapeutic benefits of adebrelimab.

Targets

DNACD274 (Programmed cell death protein 1 ligand 1)TS (Thymidylate synthase)

Beyond the preview

Go deeper on adebrelimab + XELOX.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on adebrelimab + XELOX.

Explore the full profile